

## Chordate Medical presents interim report for Q2 2023

**Chordate Medical Holding (publ) is releasing its interim report for Q2 2023 on Thursday, August 31, 2023, at 08:30. On Friday, September 1st, at 10:00, the company invites you to a webcast presentation of the report with CEO Anders Weilandt on Finwire TV.**

The presentation can be viewed through the following link: <https://www.finwire.tv/webcast/chordate-medical/q2-2023/>

Following the presentation, there will be a Q&A session where viewers can submit questions.

A recording of the presentation will be made available afterwards on the company's website <http://www.chordate.com> and on [Finwire TV's YouTube channel](#).

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

**Attachments**

[Chordate Medical presents interim report for Q2 2023](#)